

**Prospectus Supplement No. 11  
(To Prospectus dated October 14, 2015)**



**4,000,000 shares of common stock issuable upon the  
exercise of the 4,000,000 outstanding Class A warrants**

**and**

**2,000,000 shares of common stock issuable upon the  
exercise of the 4,000,000 outstanding Class B warrants**

---

This prospectus supplement No. 11 supplements the prospectus dated October 14, 2015 filed pursuant to Rule 424(b)(4) by Cerecor Inc. (the “Company” or “we”), as supplemented by the prospectus supplement No. 1 dated October 20, 2015, the prospectus supplement No. 2 dated November 13, 2015, the prospectus supplement No. 3 dated November 23, 2015, the prospectus supplement No. 4 dated December 17, 2015, the prospectus supplement No. 5 dated December 21, 2015, the prospectus supplement No. 6 dated December 29, 2015, the prospectus supplement No. 7 dated January 5, 2016, the prospectus supplement No. 8 dated January 12, 2016, the prospectus supplement No. 9 dated January 19, 2016 and the prospectus supplement No. 10 dated February 2, 2016, each filed pursuant to Rule 424(b)(3) by the Company (collectively, the “Prospectus”). Pursuant to the Prospectus, this prospectus supplement relates to the continuous offering of 4,000,000 shares of common stock underlying our Class A warrants and 2,000,000 shares of our common stock underlying Class B warrants. Each warrant was a component of a unit that we issued in our initial public offering, which closed on October 20, 2015. The components of the units began to trade separately on November 13, 2015. Each Class A warrant became exercisable on the date when the units detached and the components began to trade separately and will expire on October 20, 2018, or earlier upon redemption. Each Class B warrant became exercisable on the date the units detached and the components began to trade separately and will expire on April 20, 2017.

This prospectus supplement incorporates into our Prospectus the information contained in Item 8.01 of our attached Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on April 11, 2016.

---

You should read this prospectus supplement in conjunction with the Prospectus, including any supplements and amendments thereto. This prospectus supplement is qualified by reference to the Prospectus except to the extent that the information in this prospectus supplement supersedes the information contained in the Prospectus.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any supplements and amendments thereto.

Our common stock, the Class A warrants and the Class B warrants are traded on The NASDAQ Capital Market under the symbols “CERC,” “CERCW,” and “CERCZ,” respectively.

---

AN INVESTMENT IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. SEE THE SECTION ENTITLED “RISK FACTORS” BEGINNING ON PAGE 16 OF THE PROSPECTUS FOR A DISCUSSION OF INFORMATION THAT SHOULD BE CAREFULLY CONSIDERED IN CONNECTION WITH AN INVESTMENT IN OUR SECURITIES

---

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

---

The date of this prospectus supplement is April 11, 2016

---

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

-

**FORM 8-K**

-

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 11, 2016**

-

**Cerecor Inc.**

(Exact name of Registrant as Specified in Its Charter)

-

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37590**  
(Commission  
File Number)

**45-0705648**  
(IRS Employer Identification No.)

**400 E. Pratt Street**  
**Suite 606**  
**Baltimore, Maryland**  
(Address of Principal Executive Offices)

**21202**  
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(410) 522-8707**

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

-

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01. Regulation FD Disclosure.**

On April 11, 2016, Cerecor Inc. (the “*Company*”) issued a press release, further described in Item 8.01 below, in connection with its research and development grant award from the National Institute on Drug Abuse (“NIDA”) at the National Institutes of Health. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

***Research and Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health***

On April 11, 2016, the Company announced that it has been awarded a research and development grant of approximately \$1.0 million from NIDA. The grant provides the Company with additional resources for the ongoing Phase 2 clinical trial for CERC-501, “*A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior*”.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No</b>	<b>Description</b>
99.1	Press Release, dated April 11, 2016, entitled “Cerecor Announces \$1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health.”

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Cerecor Inc.**

By: /s/ Mariam Morris  
Mariam Morris  
Chief Financial Officer

Date: April 11, 2016

## EXHIBIT INDEX

Exhibit No	Description
99.1	Press Release, dated April 11, 2016, entitled "Cerecor Announces \$1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health."



**Cerecor Announces \$1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health**

*Grant to Co-Fund CERC-501 Phase 2 Smoking Cessation Study*

**Baltimore, MD – April 11, 2016** – Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has been awarded a grant from the National Institute on Drug Abuse (“NIDA”) at the National Institutes of Health. The grant of approximately \$1.0 million provides Cerecor with additional resources for the ongoing Phase 2 clinical trial for CERC-501, “*A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior.*”

CERC-501 is a potent and selective kappa opioid receptor (“KOR”) antagonist. “We are enthusiastic about the potential use of CERC-501 for smoking cessation as well as other addictive disorders,” said Ronald Marcus, M.D., Chief Medical Officer and Head of Regulatory Affairs of Cerecor.

KORs are believed to play key roles in modulating stress, mood and addictive behaviors. Both KORs and dynorphin, which together comprise the kappa opioid system, are upregulated by stress and chronic exposure to drugs of abuse, and are thought to mediate the negative emotional states seen in drug withdrawal and contribute to stress-induced reinstatement of drug seeking behavior.

Uli Hacksell, Ph.D., Cerecor’s CEO, President and Chairman, said: “We are most appreciative to NIDA for this grant to co-fund Clin501-201, our Phase 2 study of CERC-501 for smoking cessation, for which we expect to release top-line data in the second half of 2016. We believe the NIDA grant further validates the importance and scientific strength of the CERC-501 program.”

**About CERC-501**

CERC-501 is a potent and selective KOR antagonist being developed for adjunctive treatment of major depressive disorder (“MDD”) and to treat substance use disorders, such as nicotine, alcohol, and/or cocaine. Kappa opioid receptors have been shown to play an important role in stress, mood and addiction in animal models. CERC-501 has been observed to have positive preclinical activity in models of depression, nicotine withdrawal and alcohol dependence, and it has been generally well tolerated in three human clinical trials.

**About Cerecor**

Cerecor is a biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders. Cerecor is currently pursuing the development of two clinical Phase 2-stage product candidates: CERC-301, an oral and NR2B-specific NMDA antagonist in development as an adjunctive treatment in MDD, and CERC-501. For more information about the Company and its products, please visit: [www.cerecor.com](http://www.cerecor.com) or contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.

---

## **Forward-Looking Statements**

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of Cerecor's management but are subject to significant risks and uncertainties, including those detailed in Cerecor's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

### **Media Contact:**

MacDougall Biomedical Communications  
Joe Rayne – 781-235-3060  
ir@cerecor.com

---